Sanders Corazon (Corsee) D. sold $50K of RARE

Sanders Corazon (Corsee) D. sold 2,000 shares of Ultragenyx Pharmaceutical Inc. (RARE) at $25.05 on 2026-06-15.

Original reporting
SEC EDGAR · Sanders Corazon (Corsee) D.
Published Jun 15, 2026, 10:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 10:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RARE
Neutral
medium confidence
Mentioned
$RARE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RARENeutralLow
01

Why it matters

The newest fact is the director’s open-market sale of 2,000 shares at $25.05, totaling $50,100, with post-sale holdings of 21,095 shares.

02

Market read

This provides a fresh ownership-change datapoint but no new fundamental catalyst (no guidance, trial results, or regulatory action).

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without context on total compensation or prior sales, signal quality is limited.

Relevance 3/10Novelty 6/10Timing: SEC Form 4 filed on 2026-06-15 (transaction dated 2026-06-15)

Background

The article is an SEC Form 4 insider transaction disclosure for Ultragenyx Pharmaceutical Inc. (RARE).

Company-level read

Ticker impact

$RARENeutralMedium confidence
Context

Ultragenyx director Sanders Corazon sold 2,000 shares in an open-market transaction at $25.05 on 2026-06-15 via SEC Form 4.

Expected impact

Low likelihood of sustained price impact; any reaction is likely short-lived unless accompanied by other new catalysts.

Evidence & confidence

The filing is a director open-market sale with no 10b5-1 plan stated; however, insider sales are common and the article provides no new operational/regulatory/clinical information.

Market effects

No sector-level read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

If the sale is not under a 10b5-1 plan (article says “No”), traders may interpret it as higher near-term caution, potentially pressuring the stock briefly.

Key entities

  • Ultragenyx Pharmaceutical Inc.

    Subject of the SEC Form 4 insider transaction disclosure.

  • Sanders Corazon (Corsee) D.

    Director who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RAREMed

Ultragenyx Pharmaceutical Inc (RARE) Q3 2026 Earnings Call Highlights: Gene Therapy

Ultragenyx Pharmaceutical Inc (RARE) discontinued two gene therapy programs (GTX-102 and UX701) due to efficacy and trial advancement issues. The company is restructuring, cutting 20% of its workforce. The future of setrusumab for osteogenesis imperfecta is uncertain pending FDA discussions. R&D spending for 2027 is guided at less than $350 million, with a focus on commercial products. The company faces potential competition in the Sanfilippo syndrome type A market.

$RAREHighAI 8/10

Ultragenyx (RARE) Q3 2026 Earnings Call Transcript

Ultragenyx (RARE) reported Q3 2026 earnings, highlighting FDA approvals for GENGLYCOS and FAYUVI, two new gene therapies. The company also announced setbacks in clinical trials for GTX-102 and UX701, leading to program terminations and workforce reductions. Revenue guidance for 2026 was reaffirmed at $730M-$760M, with profitability expected in 2027. The company aims to reduce expenses by 50% by 2027.